Business
Capital Markets Day and KPI Update
Capital Markets Day and KPI Update.
About this update from Diaceutics Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 0174C\n Diaceutics PLC\n 16 June 2021\n \n \n \n \n 16 June 2021\n \n Diaceutics PLC\n (\"Diaceutics\" or \"the Company\")\n \n Capital Markets Day and KPI Update\n \n \n \n Diaceutics PLC\n \n , (\n AIM: DXRX), the diagnostic commercialisation company for precision testing will today host a virtual Capital Markets Day (\"CMD\") for investors and equity analysts, from 1pm BST. \n \n \n \n \n The event will be led by Group CEO, Peter Keeling, and members of the senior management team and will include a series of presentations, a demonstration of the DXRX SaaS platform, views from an industry expert panel including:\n \n \n · \n Pharmaceutical Partner: a senior executive within one of the world's top five pharmaceutical companies\n \n · \n Laboratory Partner: Professor Giancarlo Pruneri, Head of Pathology Fondazione IRCCS Istituto Nazionale Tumori, Milan\n \n · \n Key Opinion Leader: Dr Avi Kulkarni, SVP and R&D leader at Nasdaq listed technology firm Cognizant.\n \n In addition, there will be a strategic update from the Company, along with a live Q&A.\n \n \n \n \n \n A video replay of the presentation will be available via the Group's website post-event.\n \n \n \n \n \n To register for the DXRX Capital Markets Day or \n for any further assistance or questions relating to the event, please contact [email protected]\n \n Key Performance Indicator Updates\n \n \n \n \n \n During the presentation, as part of the strategic update, management will outline an update to a number of the Company's KPIs\n \n * \n \n demonstrating continued positive progress with the uptake of the DXRX platform and its impact on the Company's financial model\n : \n \n \n \n · \n Over 40% of sales pipeline generation for Q2 is currently represented by DXRX-enabled products on a contract value basis*\n \n \n · \n 16% increase in average sales prices per project for Pharma clients in 2021, when compared to the 2020 average contracted price*\n \n \n · \n 10% increase in Gross Margin % (excluding amortisation and travel)**\n \n \n · \n 14 client projects live on DXRX platform as at end April\n \n \n · \n Six Diagnostic Partners and 10 Pharma partners recruited onto the DXRX platform as at end April; and\n \n \n · \n 223 Lab partners ...